480 Arsenal Street
About Syros PharmaceuticalsWe are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.
Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.
121 articles with Syros Pharmaceuticals
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
12/27/2019Pharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers.
10/28/2019Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
Syros Pharmaceuticals announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 1, 2019 to report its first quarter 2019 financial results and provide a corporate update.
Syros Pharmaceuticals announced that it has priced its concurrent underwritten public offerings of 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to 1,951,844 shares of its common stock
Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock
Syros Pharmaceuticals announced that it is offering to sell, subject to market and other conditions, shares of its common stock and Class A warrants to purchase common stock, and shares of its Series A convertible preferred stock and Class A warrants to purchase common stock, in two concurrent but separate underwritten public offerings.
Presentations Highlight Syros’ Leadership in Selective CDK7 Inhibition as Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers
Syros to Present New Preclinical Data on Its Selective CDK7 Inhibitors, SY-1365 and SY-5609, at AACR Annual Meeting
Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta.
Syros to Present Initial Clinical Data from Combination Cohorts in Its Ongoing Phase 2 Trial of SY-1425 at ASH Annual Meeting
Syros Pharmaceuticals is a leader in the development of medicines that control the expression of genes.
Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Opened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination
Syros to Present Clinical and Preclinical Data on SY-1365 and Earlier-Stage Pipeline at EORTC-NCI-AACR Meeting
First Clinical Data from Phase 1 Trial of SY-1365 in Advanced Solid Tumors to be Highlighted in Oral Plenary Session
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial results and provide a corporate update.
10/25/2018What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting.
Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2018 Cantor Global Healthcare Conference
Syros Pharmaceuticals announced that its Chief Financial Officer Joseph J. Ferra will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference.
Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Plan to Open Expansion Cohorts in Phase 1 Trial of SY-1365 in Fall of 2018; Expansion to Focus on Ovarian and Breast Cancer Patient Populations as Single Agent and in Combination
Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 7, 2018 to report its second quarter 2018 financial results and provide a corporate update.
Syros Pharmaceuticals announced the appointment of Michael W. Bonney to the Company’s Board of Directors. Mr. Bonney brings extensive strategic, operational, commercial and leadership experience in the biotechnology industry.
Syros Pharmaceuticals announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences.
Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Presented Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer